Varubi Tablet
Product Images NDC 87628-101

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Varubi (NDC 87628-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Luria Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Lur0b 0000 01)

Chemical structure diagram of rolapitant, the active ingredient in Varubi. The structure shows the arrangement of atoms including fluorines, a phenyl group, and other functional groups, along with notation for hydrochloride and water molecules.*

FDA Label Image

Figure (Lur0b 0000 02)

A bar chart comparing control and rolapitant groups in terms of cumulative response rates at 1 week and 2 weeks. The chart visually shows the differences between these two conditions over the specified time periods.*

FDA Label Image

Figure (Lur0b 0000 03)

Bar chart depicting No Event Rate Monitoring percentages for Varubi (rolapitant) versus Control No at multiple cycles (2, 3, 4, 5, 6). The chart compares event rates across these cycles with numerical differences and confidence intervals noted below.*

FDA Label Image

Figure (Lur0b 0000 04)

A bar chart comparing the mean percent of baseline natural killer (NK) cells across six cycles for Control and Rolapitant 90 mg groups. The chart shows differences and 95% confidence intervals for each cycle, illustrating the effect of Rolapitant versus Control over time.*

FDA Label Image

Figure (Lur0b 0000 05)

A bar chart comparing the percentage of patients with no delayed emesis over multiple cycles for Control versus Rolapitant treatment. The y-axis indicates the percentage, while the x-axis shows different treatment cycles numbered 2 through 6. The graph highlights the difference percentage and 95% confidence intervals for each cycle.*

FDA Label Image

Figure (Lur0b 0000 06)

Varubi (rolapitant) tablets 90 mg per tablet in oral tablet form, supplied by Luria Therapeutics LLC. This packaging contains a single dose of 180 mg total dose, consisting of two 90 mg tablets. The label indicates prescription use only, provides storage instructions, and features instructions for opening and pulling to expose the bottle inside. The NDC is 87628-101-02.*

FDA Label Image

Blister Backing Label (Lur0b 0000 07)

This image shows a small square label with a black and white 2D barcode (data matrix) in the top left corner. Below the barcode, the text "Lot: XXXXXXX" and "Exp: MM YYYY" is printed, representing placeholders for lot number and expiration date. The label has a thin blue border and an outline of a capsule or tablet visible behind the text and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.